Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is now covered by analysts at Guggenheim. They set a "buy" rating and a $20.00 price target on the stock.
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CGlobeNewswire
- Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $25.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
- Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 11/12/24 - Miss
ZVRA
Sec Filings
- 11/22/24 - Form 8-K
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SC
- ZVRA's page on the SEC website